PHVS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 120380 min ago

@ $28.00

Wydano: 13 vas. 2024 @ 16:35

Zwrot: -19.00%

Poprzedni sygnał: vas. 12 - 18:18

Poprzedni sygnał: Sprzedaż

Zwrot: -7.41 %

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	56 101.00
Średni wolumen	84 943.00
Kapitalizacja rynkowa	1.22B
EPS	$0 ( 2024-04-03 )
Następna data zysków	( $-0.560 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.04
ATR14	$0.212 (0.93%)

Wolumen Korelacja

Długi: -0.15 (neutral)

Krótki: -0.84 (strong negative)

Signal:(45.11) Neutral

Pharvaris N.V. Korelacja

10 Najbardziej pozytywne korelacje
DBX	0.859
GASS	0.848
PEV	0.843
UTME	0.842
GYRO	0.841
NFBK	0.84
SFST	0.84
ANIX	0.837
SSP	0.836
ADBE	0.834

10 Najbardziej negatywne korelacje
SANG	-0.857
BWC	-0.854
GPOR	-0.854
OPGN	-0.853
NVX	-0.851
TCRX	-0.849
AIA	-0.844
EEMA	-0.844
PAE	-0.844
SEED	-0.844

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pharvaris N.V. Korelacja - Waluta/Towar

0.35
( neutral )

0.32
( neutral )

-0.34
( neutral )

0.35
( neutral )

-0.43
( neutral )

Pharvaris N.V. Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-252 271 (0.00 %)
EPS:	$-2.57

FY	2023
Przychody:	$0
Zysk brutto:	$-252 271 (0.00 %)
EPS:	$-2.57

FY	2022
Przychody:	$0
Zysk brutto:	$-150 186 (0.00 %)
EPS:	$-2.27

Financial Reports:

No articles found.

Pharvaris N.V.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.